Private investment firm Hildred Capital Partners plans to acquire a majority stake in pharmaceutical company Crown Laboratories.
Both companies involved in the transaction are based in the US.
Novartis plans to acquire Advanced Accelerator Applications (AAA) for $3.9bn.
Novartis is a pharmaceutical company based in Switzerland, while AAA is a French radiopharmaceutical company.
Neos Therapeutics, Inc. (formerly Neostx Inc.) has rejected PDL BioPharma’s plans to acquire its entire outstanding shares for $10.25 a share.
Both pharmaceutical companies involved in the transaction are based in the US.
Alembic Pharmaceuticals has acquired generic drug developer Orit Laboratories.
The acquisition enables the Indian pharmaceutical company to expand its footprint in the US.
US-based biotechnology company Amgen plans to acquire the remaining 50% stake in Kirin-Amgen, a joint venture (JV) between integrated beverage company Kirin Holdings and Amgen.
The JV will pay $780m to Kirin and consequently become a wholly owned subsidiary of Amgen.